We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
18
Jun 2026
A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.
18
Jun 2026
A JCI review traces biological age measurement from functional tests and blood biomarkers to epigenetic, proteomic, imaging, wearable, and AI-based clocks. It finds that these tools can improve risk prediction beyond chronological age, but standardization, interpretability, and prospective validation are needed before routine clinical use.
18
Jun 2026
Scenario-based modeling projects that aviation-related air pollution could drive a major rise in premature deaths by 2040, mainly through PM2.5 and ozone exposure. The study estimates that aircraft emissions caused 33,900 PM2.5-related deaths and 24,600 ozone-related deaths in 2019, with baseline 2040 deaths projected to more than double.
17
Jun 2026
This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, and extracellular vesicles, may shape obesity and type 2 diabetes through the microbiota-gut-brain axis.